SUPERNUS PHARMACEUTICALS INC's ticker is SUPN and the CUSIP is 868459108. A total of 211 filers reported holding SUPERNUS PHARMACEUTICALS INC in Q3 2020. The put-call ratio across all filers is 3.03 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $8,354 | -99.9% | 303 | -99.9% | 0.00% | -100.0% |
Q2 2023 | $13,496,790 | +36.5% | 448,995 | +62.0% | 0.05% | +5.9% |
Q4 2022 | $9,886,618 | +308.0% | 277,169 | +205.0% | 0.05% | +64.5% |
Q3 2021 | $2,423,000 | -18.1% | 90,866 | -5.4% | 0.03% | -26.2% |
Q2 2021 | $2,957,000 | +103.5% | 96,034 | +73.0% | 0.04% | +68.0% |
Q1 2021 | $1,453,000 | +212.5% | 55,516 | +200.1% | 0.02% | +177.8% |
Q4 2020 | $465,000 | +44.9% | 18,500 | +20.0% | 0.01% | +28.6% |
Q3 2020 | $321,000 | +68.9% | 15,423 | +92.4% | 0.01% | +75.0% |
Q2 2020 | $190,000 | -5.5% | 8,017 | -20.6% | 0.00% | 0.0% |
Q1 2020 | $201,000 | -59.4% | 10,100 | -51.6% | 0.00% | -81.8% |
Q4 2019 | $495,000 | -22.7% | 20,851 | -10.5% | 0.02% | +57.1% |
Q3 2019 | $640,000 | +18.7% | 23,303 | +43.0% | 0.01% | +7.7% |
Q2 2019 | $539,000 | +9.3% | 16,298 | +15.9% | 0.01% | -7.1% |
Q1 2019 | $493,000 | +24.2% | 14,058 | +17.5% | 0.01% | 0.0% |
Q4 2018 | $397,000 | – | 11,960 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 426,500 | $11,754,340 | 3.96% |
ASHFORD CAPITAL MANAGEMENT INC | 916,747 | $25,274,715 | 3.72% |
ARMISTICE CAPITAL, LLC | 5,092,000 | $140,386,440 | 2.15% |
S&T BANK/PA | 215,578 | $5,943 | 1.15% |
Aristotle Capital Boston, LLC | 1,187,981 | $32,752,634 | 1.06% |
RICE HALL JAMES & ASSOCIATES, LLC | 544,468 | $15,010,983 | 0.95% |
Tributary Capital Management, LLC | 352,429 | $9,716,468 | 0.92% |
Bridge City Capital, LLC | 65,297 | $1,800,238 | 0.91% |
Integral Health Asset Management, LLC | 220,000 | $6,065,400 | 0.84% |
Retirement Planning Co of New England, Inc. | 51,608 | $1,422,833 | 0.79% |